

ABSTRACT TEMPLATE for Company Presentations

Questions for categories: Biotech/Pharma or Medical Devices or Health IT/Digital

- o **Investment Rational**

Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures; and management strengths.

BrainQ is developing a home therapy for stroke recovery and aims to create a new SOC for over 100M stroke survivors right now. We have developed a cloud-connected therapeutic medical device that creates frequency tuned low-intensity electromagnetic field therapy - that aims to facilitate neuro recovery processes. The system is patient-friendly, scalable, and accessible with embedded digital health and telemedicine tools. The company has received a breakthrough device designation and is currently in its pivotal study, Emagine, with some of the top academic sites worldwide.

- o **Business Strategy**

Technology is aimed for the DME model, to be used at home, following a limited number of training sessions. As such it will be prescribed by neurologists and PM&R and will then be distributed to patients in a D2C way. A good example in Novocure

- o **Core Technology**

What is the technology, its uniqueness, and its value proposition?

BrainQ has two main novelties, tailoring the EMF to target impaired networks in the brain using explanatory ML analysis on brainwaves. The latter has shown striking efficacy in an RCT pilot. As well as developing a cloud-connected wearable that fits patient's fragmented recovery pathway and can be used at scale

- o **Product Profile/Pipeline**

Briefly describe the company's product/pipeline, current status and market potential. Discuss milestones, potential collaborations and partnerships.

Our first indication to Market is Ischemic Stroke recovery for patients with moderate to severe disability. Followed by several more indications in pipeline: PD, AD, MS, TBI, SCI

- o **What's Next?**

The main focus is the execution of the pivotal study as well as setting the ground for commercialization. The company is well funded, having its \$40M B round less than a year ago led by Hanaco, Peregrine, and Dexcel Pharma